• Home
  • Careers

Company Vision

To redefine the life of the spinal cord injury patient.

Press Releases

InVivo Therapeutics Announces Closing of $3.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules April 17, 2020

InVivo Therapeutics Announces $3.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules April 15, 2020

InVivo Therapeutics Announces Closing of $7.0 Million Public Offering March 11, 2020

InVivo Therapeutics Announces Pricing of $7.0 Million Public Offering March 6, 2020

InVivo Therapeutics Announces Reverse Stock Split February 3, 2020


Learn More About Our Clinical Trials

Research & Clinical Development Preview

_0006_Pressure ulcers

Click here to learn more

CEO's Perspective

“As evidenced by the passing of the 21st Century Cures Act, regulators and policy makers have recently highlighted the benefits and utility of Real-World Evidence (RWE) as it pertains to the Food and Drug Administration (FDA) regulatory decision-making for medical devices. RWE is derived from Real World Data (RWD) collected outside of a traditional clinical trial and includes sources such as patient registries. InVivo is committed to providing regulatory agencies with a comprehensive benchmark comparator dataset using RWE to help support the assessment of the safety and probable benefit of its Neuro-Spinal Scaffold™. ” For full text, click here.

Mark Perrin, CEO and Chairman, 5/30/2017